US_Oncol_Contents.qxp 27/11/08 10:53 Page 4
Contents
Advisory Panel
8
Foreword
10
Matti S Aapro, MD
Executive Director, International Society for Geriatric Oncology (SIOG)
Current Issues
The Current Role of Sentinel Lymph Node Biopsy in Breast, Melanoma,
and Gastrointestinal Cancers 11
Byron E Wright, MD, FACS
1
and Armando E Giuliano, MD, FACS
2
1. Surgical Oncology Fellow; 2. Chief of Science and Medicine, and Director, Breast Center, John Wayne Cancer
Institute at Saint John’s Health Center
The p53 Tumor-suppressor Gene—Inhibiting Tumor Angiogenesis 15
Jose G Teodoro, PhD
Virologist and Cancer Biologist, Goodman Cancer Center, and Assistant Professor, Department of Biochemistry,
Faculty of Medicine, McGill University
Supportive Oncology
Chemotherapy-induced Nausea and Vomiting 19
Karen M Mustian, PhD, Tom V Darling, PhD, Michelle C Janelsins, PhD, Pascal Jean-Pierre, PhD,
Joseph A Roscoe, PhD and Gary R Morrow, PhD
James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry
Lung Cancer
Predicting Metastatic Behavior in Lung Adenocarcinoma 24
Ioannis Boukovinas, MD, PhD
1
and Paris A Kosmidis, MD
2
1. Consultant Medical Oncologist, Theagenion Cancer Hospital, Thessaloniki; 2. Head, Second Medical Oncology
Department, ‘HYGEIA’ Hospital, Athens
Unmet Needs in the Treatment of Metastatic Non-small-cell Lung Cancer 27
Ji-Youn Han, MD, PhD
1
and Jin Soo Lee, MD, PhD
2
1. Chief, Lung Cancer Branch; 2. President, Research Institute and Hospital, National Cancer Center, Korea
First-line Treatment of Metastatic Lung Cancer—New Developments 31
Grace K Dy, MD
1
and Alex A Adjei, MD, PhD
2
1. Attending Physician and Assistant Professor of Medicine, Department of Medicine; 2. Senior Vice President
of Clinical Research, Chair, Department of Medicine, and Katherine Anne Gioia Chair in Cancer Medicine,
Roswell Park Cancer Institute
Breast Cancer
Developments in Breast Cancer Treatment—Epidermal Growth Factor
Receptor and Human Epidermal Growth Factor Receptor 2 Inhibitors 34
Norma O’Donovan, PhD
1
and John Crown, MD, MPH
1,2
1. National Institute for Cellular Biotechnology, Dublin City University; 2. Department of Medical Oncology,
St Vincent’s University Hospital, Dublin
Ovarian Cancer
Phenoxodiol—A Chemosensitizer in the Midst of Cancer Chemoresistance 39
Ayesha B Alvaro, MD,
1
Patricia Rossi, MD,
2
David Brown,
2
Aliza Leiser,
1
Michael Kelly,
1
Thomas Rutherford,
1
Alan Husband, MD, PhD
2
and Gil Mor, MD, PhD
1
1. Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine;
2. Novogen Ltd.
4 US ONCOLOGY